BofA has initiated coverage of Candel Therapeutics (NASDAQ:CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. "While approved therapies may ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

Fintel reports that on February 7, 2025, B of A Securities initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy recommendation. As of January 29, 2025, the average one-year price ...

Candel Therapeutics, Inc. (NASDAQ:CADL) insiders who acquired shares over the previous 12 months, can probably afford to ignore the recent 19% decline in the stock price. After accounting for the ...

Shares of Candel Therapeutics surged after its board chair picked up 1.25 million shares of the company. The stock gained 44% at $9.39 on Thursday. Shares are up over 760% for the past year.

Bullish option flow detected in Candel Therapeutics (CADL) Inc with 3,986 calls trading, 3x expected, and implied vol increasing almost 24 points to 171.94%. Dec-24 7 calls and Jan-25 4 puts are ...